(Q50643049)

17 March 2018

title

Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy. (English)

1 reference

17 March 2018

main subject

anti-retroviral agent

0 references

1 reference

2

1 reference

17 March 2018

Anita Palepu

5

1 reference

17 March 2018

Martin T. Schechter

8

1 reference

17 March 2018

author name string

A H Anis

1

1 reference

17 March 2018

X H Wang

3

1 reference

17 March 2018

B Yip

4

1 reference

17 March 2018

J S Montaner

6

1 reference

17 March 2018

M V O'Shaughnessy

7

1 reference

17 March 2018

publication date

1 June 1998

1 reference

17 March 2018

published in

PharmacoEconomics

1 reference

17 March 2018

volume

13

1 reference

17 March 2018

issue

6

1 reference

17 March 2018

page(s)

697-705

1 reference

17 March 2018

The economic impact of AIDS in the United States

cites work

1 reference

12 December 2020

Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland

1 reference

12 December 2020

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

12 December 2020

Regression analysis for correlated data

1 reference

12 December 2020

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

1 reference

12 December 2020

The distinction between cost and charges

1 reference

12 December 2020

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel

1 reference

12 December 2020

Modelling the Cost Effectiveness of Lamivudine/Zidovudine Combination Therapy in HIV Infection

1 reference

12 December 2020

Average annual drug cost and its determinants in a population based cohort of HIV-positive adult men and women

1 reference

12 December 2020

Interim proposal for a WHO Staging System for HIV infection and Disease

1 reference

12 December 2020

Models for longitudinal data: a generalized estimating equation approach

1 reference

12 December 2020

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

12 December 2020

Current controversies in the treatment of HIV infection and AIDS. An economic perspective

1 reference

12 December 2020

Leads from the MMWR. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome

1 reference

12 December 2020

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

1 reference

12 December 2020

Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991.

1 reference

12 December 2020

Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion

1 reference

12 December 2020

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

12 December 2020

Combination antiretroviral therapy in HIV infection. An economic perspective

1 reference

12 December 2020

Cost Effectiveness of Low-Dose Zidovudine Therapy for Asymptomatic Patients with Human Immunodeficiency Virus (HIV) Infection

1 reference

12 December 2020

10.2165/00019053-199813060-00006

Identifiers

DOI

1 reference

17 March 2018

Dimensions Publication ID

1048200509

0 references

1 reference

17 March 2018